English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 28 May 2024, 16:28 HKT/SGT
CR Pharmaceutical Armed with Leading Advantages Releases Growth Potential and Achieves High-quality Sustainable Development

HONG KONG, May 28, 2024 - (ACN Newswire) - China Resources Pharmaceutical Group Limited (“CR Pharmaceutical” or the “Group”) (stock code: 3320.HK), recorded total revenue of RMB244,703.9 million last year, a 12.2% climb year-on-year, and net profit of RMB 7,775.0 million, a 16.8% increase year-on-year. Profit attributable to owners of the Company was RMB3,854.2 million, up 10.1% year-on-year. Earnings of the Group continued to grow, and its performance potential gradually releasing in the post-pandemic.

Synergistic Development of Three Major Business Segments with Leading Advantages in Distribution Business

CR Pharmaceutical is a leading state-owned pharmaceutical enterprise. It owns such subsidiaries as CR Double-Crane, CR Sanjiu, CR Jiangzhong, Dong-E-E-Jiao, CR Boya Biopharmaceutical, and CR Zizhu, all with priding brand advantages and star products. The Group’s three major business segments, namely pharmaceutical manufacturing, pharmaceutical distribution and pharmaceutical retail businesses, have been developing in synergy and realizing steady growth. Among them, pharmaceutical distribution business contributes approximately 80% of the Group’s revenue. As the third largest distributor of pharmaceutical products in China, the Group’ distribution network covers 28 provinces serving approximately 240 thousand clients and it also operates more than 230 logistics centres. Moreover, CR Pharmaceutical runs 790 self-owned retail pharmacies, including 272 DTP pharmacies. The Group has also continuously promoted professional development and the deployment along the full-value industrial chain of medical devices, with 40 independent medical device companies already established and digital transformation picking up speed, all conducive to consolidating its position as a leading pharmaceutical distribution company.

"External Mergers and Acquisitions + Integration of Internal Resources" – The Two Wheels Driving High-quality Development

CR Pharmaceutical has continued to expand its business footprint via extensive development, mergers and acquisitions. In 2023, the Group successively acquired relevant stakes in KPC Pharmaceuticals, Anhui Lifang Pharmaceutical and Sichuan Kelun Medicine & Trade to bolster the competitiveness of its core business, improve its competitive advantage in the out-of-hospital market in Anhui Province and boost its market share in South-western China. At the same time, the Group has continued to promote synergistic integration of internal resources to optimise business layout. In March 2024, CR Double-Crane completed acquiring 100% stake in CR Zizhu, allowing it to consolidate its chemical drugs business and enhance synergies. Those measures will help promote the performance of regional businesses and segments of the Group in the future, enabling it to achieve high-quality development.

Embraces SOE Reform and Stock Incentive Plans Contribute to Sustainable Growth

In January 2024, with new strategic investors introduced, CR Pharmaceutical Commercial optimised its capital structure. In January 2023, completing B-round financing of RMB600 million, CR Biopharm further enhanced its mixed-ownership reform. The Group has also actively promoted stock incentive plans. Its subsidiaries, including Dong-E-E-Jiao, CR Jiangzhong, CR Sanjiu and CR Double-Crane, have continued to implement such plans to help the Group achieve sustainable and stable growth and release its performance potential.

The Group achieved satisfactory results in the first quarter of 2024. Its subsidiaries, including CR Double-Crane, CR Sanjiu, CR Jiangzhong and Dong-E-E-Jiao, recorded net profits attributable to owners of the parent company of RMB416 million, RMB1,364 million, RMB267 million and RMB353 million, respectively, up by 11.00%, 18.49%, 9.99% and 53.43% year-on-year. Good performances are expected to positively affect the Group’s long-term growth.


Topic: Press release summary Sectors: Daily Finance, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
SUMMER WEB3FEST 2024: A Resounding Success and a Glimpse into the Future  
June 21, 2024 10:00 HKT/SGT
Scotts Miracle-Gro (SMG) Investor Alert: Kaplan Fox & Kilsheimer LLP Encourages Investors to Contact the Firm in Scotts Securities Fraud Class Action  
June 20, 2024 20:32 HKT/SGT
GDA Capital & Coinweb Launch The Next Top Blockchain Startup Competition with a $200k+ Prize Pool to Fuel Innovation and Growth in Web3  
June 20, 2024 20:30 HKT/SGT
Envision Greenwise (01783) Launches Hong Kong's First EV Battery Processing Plant, Boosting Global Recycling Efforts  
June 20, 2024 19:00 HKT/SGT
INVEST FAIR 2024-Kuala Lumpur: Navigating the Future of Investing "Money - Finance - Technology"  
June 20, 2024 16:00 HKT/SGT
Fosun's Replicable Global Operational Capabilities Poised for Robust Revaluation  
June 20, 2024 15:00 HKT/SGT
EPB Group Berhad Signs on Malacca Securities as Underwriter  
June 20, 2024 14:00 HKT/SGT
NEC and Ursa Space collaborate on satellite image analysis services using one of the world's largest virtual constellations  
Thursday, June 20, 2024 12:20:00 PM
Mobile-health Network Solutions [MaNaDr] to Offer GLP-1 Injectables for Medical Weight Loss from USD10/Day  
June 20, 2024 09:00 HKT/SGT
MSG Officials: Papua Is Stable and Conducive Overall  
June 20, 2024 03:00 HKT/SGT
More Press release >>
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575